Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Affiliations

• ¹ UPMC Hillman Cancer Center, Pittsburgh, PA, USA. [email protected].
• ² Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• ³ NYU Langone Medical Center, New York, NY, USA.
• ⁴ Medizinische Universität Wien, Vienna, Austria.
• ⁵ Hôpital de la Timone, Marseille, France.
• ⁶ Elbe Klinikum Buxtehude, Buxtehude, Germany.
• ⁷ University Medical Center Mainz, Mainz, Germany.
• ⁸ Hôpital Saint André, Bordeaux, France.
• ⁹ Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
• ¹⁰ Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
• ¹¹ Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
• ¹² Charles University Third Faculty of Medicine and University Hospital Královské Vinohrady, Prague, Czech Republic.
• ¹³ Nantes University Hospital, Nantes, France.
• ¹⁴ University of Western Australia and Sir Charles Gairdner Hospital, Perth, WA, Australia.
• ¹⁵ Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
• ¹⁶ Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
• ¹⁷ Bristol Myers Squibb, Princeton, NJ, USA.
• ¹⁸ Cleveland Clinic, Cleveland, OH, USA.